Cargando…
Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report
BACKGROUND: Typhoid fever remains an important public health problem in developing countries and is endemic in many parts of Asia and Africa where the incidence of disease typically peaks in school-aged children. Age restrictions and other limitations of existing oral live-attenuated typhoid and par...
Autores principales: | Capeding, Maria Rosario, Alberto, Edison, Sil, Arijit, Saluja, Tarun, Teshome, Samuel, Kim, Deok Ryun, Park, Ju Yeon, Yang, Jae Seung, Chinaworapong, Suchada, Park, Jiwook, Jo, Sue-Kyoung, Chon, Yun, Yang, Seon-Young, Ham, Dong Soo, Ryu, Ji Hwa, Lynch, Julia, Kim, Jerome H., Kim, Hun, Excler, Jean-Louis, Wartel, T. Anh, Sahastrabuddhe, Sushant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273193/ https://www.ncbi.nlm.nih.gov/pubmed/31585725 http://dx.doi.org/10.1016/j.vaccine.2019.09.074 |
Ejemplares similares
-
Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study
por: Capeding, Maria Rosario, et al.
Publicado: (2020) -
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
por: Capeding, Maria Rosario, et al.
Publicado: (2018) -
A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age
por: Carlos, Josefina Cadorna, et al.
Publicado: (2022) -
Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose
por: Capeding, Maria Rosario, et al.
Publicado: (2022) -
Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)
por: Lee, Eun Young, et al.
Publicado: (2020)